Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases

Science

Volumn 282, Issue 5394, 1998, Pages 1717-1721

  Caron, Emmanuelle ^a   Hall, Alan ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN G; RHO FACTOR;

ANIMAL CELL; ARTICLE; CYTOKINE PRODUCTION; ENZYME MECHANISM; ENZYME REGULATION; MOUSE; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RESPIRATORY BURST; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 0032573378     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.282.5394.1717     Document Type: Article

References (38)

1. L.-A. H. Allen and A. Aderem, Curr. Opin. Immunol. 8, 36 (1996).
2. S. L. Newman, L. K. Mikus, M. A. Tucci, J. Immunol. 146, 967 (1991); L.-A. H. Allen and A. Aderem, J. Exp. Med. 184, 627 (1996).
3. S. L. Newman, L. K. Mikus, M. A. Tucci, J. Immunol. 146, 967 (1991); L.-A. H. Allen and A. Aderem, J. Exp. Med. 184, 627 (1996).
4. G. Kaplan, Scand. J. Immunol. 6, 797 (1977).
5. A. A. Aderem, S. D. Wright, S. C. Silverstein, Z. A. Cohn, J. Exp. Med. 161, 617 (1985).
6. S. D. Wright and S. C. Silverstein, ibid. 158, 2016 (1983); K. Yamamoto and R. B. Johnston, ibid. 159, 405 (1984).
7. S. D. Wright and S. C. Silverstein, ibid. 158, 2016 (1983); K. Yamamoto and R. B. Johnston, ibid. 159, 405 (1984).
8. P. R. Scholl, D. Ahern, R. S. Geha, J. Immunol. 149, 1751 (1992); M. Stein and S. Gordon, Eur. J. Immunol. 21, 431 (1991).
9. P. R. Scholl, D. Ahern, R. S. Geha, J. Immunol. 149, 1751 (1992); M. Stein and S. Gordon, Eur. J. Immunol. 21, 431 (1991).
10. A. Hall, Science 279, 509 (1998).
11. A. J. Ridley and A. Hall, Cell 70, 389 (1992); A. J. Ridley, H. F. Paterson, C. L. Johnston, D. Diekmann, A. Hall, ibid., p. 401; R. Kozma, S. Ahmed, A. Best, L. Lim, Mol. Cell. Biol. 15, 1942 (1995).
12. A. J. Ridley and A. Hall, Cell 70, 389 (1992); A. J. Ridley, H. F. Paterson, C. L. Johnston, D. Diekmann, A. Hall, ibid., p. 401; R. Kozma, S. Ahmed, A. Best, L. Lim, Mol. Cell. Biol. 15, 1942 (1995).
13. A. J. Ridley and A. Hall, Cell 70, 389 (1992); A. J. Ridley, H. F. Paterson, C. L. Johnston, D. Diekmann, A. Hall, ibid., p. 401; R. Kozma, S. Ahmed, A. Best, L. Lim, Mol. Cell. Biol. 15, 1942 (1995).
14. C. D. Nobes and A. Hall, Cell 81, 53 (1995).
15. R. Perona et al., Genes Dev. 11, 463 (1997).
16. O. A. Coso et al., Cell 81, 1137 (1995); A. Minden, A. Lin, F.-X. Claret, A. Abo, M. Karin, ibid., p. 1147; H. Teramoto et al., J. Biol. Chem. 271, 25731 (1996); A. Abo et al., Nature 353, 668 (1991); T. G. Gabig, C. D. Crean, P. L. Mantel, R. Rosli, Blood 85, 804 (1995).
17. O. A. Coso et al., Cell 81, 1137 (1995); A. Minden, A. Lin, F.-X. Claret, A. Abo, M. Karin, ibid., p. 1147; H. Teramoto et al., J. Biol. Chem. 271, 25731 (1996); A. Abo et al., Nature 353, 668 (1991); T. G. Gabig, C. D. Crean, P. L. Mantel, R. Rosli, Blood 85, 804 (1995).
18. O. A. Coso et al., Cell 81, 1137 (1995); A. Minden, A. Lin, F.-X. Claret, A. Abo, M. Karin, ibid., p. 1147; H. Teramoto et al., J. Biol. Chem. 271, 25731 (1996); A. Abo et al., Nature 353, 668 (1991); T. G. Gabig, C. D. Crean, P. L. Mantel, R. Rosli, Blood 85, 804 (1995).
19. O. A. Coso et al., Cell 81, 1137 (1995); A. Minden, A. Lin, F.-X. Claret, A. Abo, M. Karin, ibid., p. 1147; H. Teramoto et al., J. Biol. Chem. 271, 25731 (1996); A. Abo et al., Nature 353, 668 (1991); T. G. Gabig, C. D. Crean, P. L. Mantel, R. Rosli, Blood 85, 804 (1995).
20. O. A. Coso et al., Cell 81, 1137 (1995); A. Minden, A. Lin, F.-X. Claret, A. Abo, M. Karin, ibid., p. 1147; H. Teramoto et al., J. Biol. Chem. 271, 25731 (1996); A. Abo et al., Nature 353, 668 (1991); T. G. Gabig, C. D. Crean, P. L. Mantel, R. Rosli, Blood 85, 804 (1995).
21. 2 antimouse IgG, was used to detect receptor expression. Rhodamine-labeled phalloidin (Sigma) was used to visualize F-actin. To block the nonspecific binding of antibodies to the Fc receptor, we performed incubations with antibodies when appropriate in the presence of excess human IgGs.
22. COS-1 cells were transfected by the DEAE-dextran method as described [M. F. Olson, A. Ashworth, A. Hall, Science 269, 1270 (1995)]. Plasmid amounts in each 10-cm petri dish were as follows: 4 μg of pRK5-FcγRIIA, or 2 μg of pRK5-CD11b and 2 μg of pRK5-CD18, with either 1 μg of pRK5myc, 1 μg of pEFmyc-C3 transferase, or one of the Rho, Rac, and Cdc42 constructs (1 μg). Twenty-four hours later, cells were serum-starved for 16 hours before phagocytic challenge and immunofluorescence. Sheep RBCs (Cappel, Thame, UK) were coated with IgG (IgG-RBCs) or with C3bi (C3bi-RBCs) as follows. RBCs in gelatin veronal buffer were incubated in the presence of subagglutining concentrations of IgG or IgM antibodies to rabbit RBCs (Cappel). RBCs were then washed, and IgM-coated RBCs were further opsonized by incubation with 10% (v/v) C5-deficient human serum for 20 min at 37°C. Under these conditions, C3b is rapidly fixed to IgM-coated RBCs and is completely converted into C3bi [S. L. Newman and L. K. Mikus, J. Exp. Med. 161, 1414 (1985)]. Opsonization was checked by fluorescence after incubation with FITC-conjugated anti-rabbit IgG or with goat anti-C3 (Sigma) followed by FITC-conjugated anti-goat IgG. All IgG-RBCs and C3bi-RBCs appeared to be uniformly labeled. After a final wash, the RBCs were suspended in Hepes-buffered Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL) and added to cells at a ratio of ∼10 RBCs per cell. For phagocytosis assays, complement-opsonized RBCs were allowed to interact for 20 min at 37°C with transfected COS cells. IgG-opsonized RBCs were allowed to adhere to cells for 15 min at 4°C, then unbound RBCs were washed off and phagocytes were further incubated for 15 min at 37°C in Hepes-buffered DMEM. After fixation and immunofluores3 cence, transfected COS cells were scored for their ability to bind or phagocytose RBCs (14). COS cells were examined for phagocytic receptor (control) or Myc expression (cotransfection with Myc-tagged constructs), and only the positive cells were analyzed for RBC binding or phagocytosis. Positive cells represented ∼20% of the total number of COS cells per cover slip, that is, ≥100 cells per cover slip. Rhodamine-conjugated donkey anti-rabbit IgGs were used to detect RBCs. An attachment was defined by the ability of injected or transfected cells to bind one or more RBCs. Phagocytosis was defined by the ability of transfected cells to internalize one or more RBCs. No difference was observed in the total number of particles binding to the different transfectant populations.
23. COS-1 cells were transfected by the DEAE-dextran method as described [M. F. Olson, A. Ashworth, A. Hall, Science 269, 1270 (1995)]. Plasmid amounts in each 10-cm petri dish were as follows: 4 μg of pRK5-FcγRIIA, or 2 μg of pRK5-CD11b and 2 μg of pRK5-CD18, with either 1 μg of pRK5myc, 1 μg of pEFmyc-C3 transferase, or one of the Rho, Rac, and Cdc42 constructs (1 μg). Twenty-four hours later, cells were serum-starved for 16 hours before phagocytic challenge and immunofluorescence. Sheep RBCs (Cappel, Thame, UK) were coated with IgG (IgG-RBCs) or with C3bi (C3bi-RBCs) as follows. RBCs in gelatin veronal buffer were incubated in the presence of subagglutining concentrations of IgG or IgM antibodies to rabbit RBCs (Cappel). RBCs were then washed, and IgM-coated RBCs were further opsonized by incubation with 10% (v/v) C5-deficient human serum for 20 min at 37°C. Under these conditions, C3b is rapidly fixed to IgM-coated RBCs and is completely converted into C3bi [S. L. Newman and L. K. Mikus, J. Exp. Med. 161, 1414 (1985)]. Opsonization was checked by fluorescence after incubation with FITC-conjugated anti-rabbit IgG or with goat anti-C3 (Sigma) followed by FITC-conjugated anti-goat IgG. All IgG-RBCs and C3bi-RBCs appeared to be uniformly labeled. After a final wash, the RBCs were suspended in Hepes-buffered Dulbecco's modified Eagle's medium (DMEM) (Gibco-BRL) and added to cells at a ratio of ∼10 RBCs per cell. For phagocytosis assays, complement-opsonized RBCs were allowed to interact for 20 min at 37°C with transfected COS cells. IgG-opsonized RBCs were allowed to adhere to cells for 15 min at 4°C, then unbound RBCs were washed off and phagocytes were further incubated for 15 min at 37°C in Hepes-buffered DMEM. After fixation and immunofluores3 cence, transfected COS cells were scored for their ability to bind or phagocytose RBCs (14). COS cells were examined for phagocytic receptor (control) or Myc expression (cotransfection with Myc-tagged constructs), and only the positive cells were analyzed for RBC binding or phagocytosis. Positive cells represented ∼20% of the total number of COS cells per cover slip, that is, ≥100 cells per cover slip. Rhodamine-conjugated donkey anti-rabbit IgGs were used to detect RBCs. An attachment was defined by the ability of injected or transfected cells to bind one or more RBCs. Phagocytosis was defined by the ability of transfected cells to internalize one or more RBCs. No difference was observed in the total number of particles binding to the different transfectant populations.
24. S. Greenberg, J. el Khoury, E. Kaplan, S. C. Silverstein, J. Immunol. Methods 139, 115 (1991). Surface-bound particles appear to be small, have a crenated appearance, are readily distinguished from internalized particles that are enclosed in a vacuole, and have a swollen circular appearance. In our hands, this method and the counting of RBC stained pre-and post-permeabilization with different conjugates resulted in similar quantitative results in COS-1 and J774 cells.
25. I. Just et al., Nature 375, 500 (1995). Pretreatment (2 hours) of J774.A1 cells with toxin B inhibited (in a dose-dependent manner) both CR3-and FcγR-mediated phagocytosis [maximal reductions of 92 and 88%, respectively, with toxin B (10 ng/ml)] but had no effect on the initial binding of opsonized targets to J774 macrophages.
26. 5 cells per milliliter in each well. Cells were serum-starved immediately before microinjection. Biotin dextran (2.5 mg/ml) (Molecular Probes, Eugene, OR) was injected alone or with eukaryotic expression vectors (0.1 mg/ml) encoding Myc-tagged GTPase constructs into the nucleus of at least 50 cells over a period of 10 min. Cells were returned to the incubator for 3 hours for optimal expression. RBCs were opsonized, and phagocytic assay and immunofluorescence were performed as described (13). The two modifications that we introduced were (i) the preactivation of J774 cells for 15 min at 37°C with phorbol 12-myristate 13-acetate (150 ng/ml) in serum-free medium before the phagocytic challenge with CR3 targets and (ii) the visualization of microinjected cells after staining with cascade blue-conjugated avidin (Molecular Probes). To block nonspecific binding of antibodies to the Fc receptor, we performed incubations with antibodies in the presence of excess human or murine IgGs. All injected (cascade blue positive) J774.A1 control cells or all Myc-expressing macrophages were assessed (that is, ≥50 cells per condition). Microinjection did not affect viability or morphology nor did it interfere with the cell's ability to bind targets. The percentage of phagocytosis-competent cells was similar in uninjected cells and cells that were injected with biotin dextran.
27. K. Nagata, M. Driessens, N. Lamarche, J. Gorski, A. Hall, J. Biol. Chem. 273, 15453 (1998).
28. D. Cox et al., J. Exp. Med. 186, 1487 (1997).
29. D. J. Hackam, O. D. Rotstein, A. Schreiber, W.-J. Zhang, S. Grinstein, ibid., p. 955.
30. L. Van Aelst and C. D'Souza-Schorey, Genes Dev. 11, 2295 (1997).
31. K. L. Rhoades, S. H. Golub, J. S. Economou, J. Biol. Chem. 267, 22102 (1992); J. C. Lee et al., Nature 372, 739 (1994).
32. K. L. Rhoades, S. H. Golub, J. S. Economou, J. Biol. Chem. 267, 22102 (1992); J. C. Lee et al., Nature 372, 739 (1994).
33. V. A. Fadok et al., J. Clin. Invest. 101, 890 (1998); D. M. Mosser and P. J. Edelson, J. Immunol. 135, 2785 (1985); Nature 327, 329 (1987); T. J. Holzer, K. E. Nelson, R. G. Crispen, B. R. Andersen. Infect. Immun. 51, 514 (1986); L. S. Schlesinger and M. A. Horwitz, J. Clin. Invest. 85, 1304 (1990).
34. V. A. Fadok et al., J. Clin. Invest. 101, 890 (1998); D. M. Mosser and P. J. Edelson, J. Immunol. 135, 2785 (1985); Nature 327, 329 (1987); T. J. Holzer, K. E. Nelson, R. G. Crispen, B. R. Andersen. Infect. Immun. 51, 514 (1986); L. S. Schlesinger and M. A. Horwitz, J. Clin. Invest. 85, 1304 (1990).
35. V. A. Fadok et al., J. Clin. Invest. 101, 890 (1998); D. M. Mosser and P. J. Edelson, J. Immunol. 135, 2785 (1985); Nature 327, 329 (1987); T. J. Holzer, K. E. Nelson, R. G. Crispen, B. R. Andersen. Infect. Immun. 51, 514 (1986); L. S. Schlesinger and M. A. Horwitz, J. Clin. Invest. 85, 1304 (1990).
36. V. A. Fadok et al., J. Clin. Invest. 101, 890 (1998); D. M. Mosser and P. J. Edelson, J. Immunol. 135, 2785 (1985); Nature 327, 329 (1987); T. J. Holzer, K. E. Nelson, R. G. Crispen, B. R. Andersen. Infect. Immun. 51, 514 (1986); L. S. Schlesinger and M. A. Horwitz, J. Clin. Invest. 85, 1304 (1990).
37. V. A. Fadok et al., J. Clin. Invest. 101, 890 (1998); D. M. Mosser and P. J. Edelson, J. Immunol. 135, 2785 (1985); Nature 327, 329 (1987); T. J. Holzer, K. E. Nelson, R. G. Crispen, B. R. Andersen. Infect. Immun. 51, 514 (1986); L. S. Schlesinger and M. A. Horwitz, J. Clin. Invest. 85, 1304 (1990).
38. This work was generously supported by a Cancer Research Campaign (UK) program grant. E.C. was the recipient of a Training and Mobility of Researchers fellowship from the European Union. We thank B. Seed for human FcγRIIA, A. Law for CD11b and CD18, B. Wren for purified toxin B, and C D. Nobes and L. M. Machesky for their constructive help and useful discussions throughout this work.